Pipeline

PROGRAM

DISEASE

DISCOVERY

PRE-CLINICAL

PHASE 1/2

PIVOTAL

AML

WU-NK-101

Head & Neck Cancer

WU-NK-101 + Cetuximab

WU-NK

Melanoma

WU-NK-101 (post-checkpoint inhibitor)

Undisclosed

WU-NK-201

T-ALL/T-NHL

WU-CART-007

WU-CART

T-NHL

WU-CART-002

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
T-NHL = T-cell Non-Hodgkin’s Lymphoma

Next in our story
Scroll to Top